http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110950956-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
| filingDate | 2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110950956-B |
| titleOfInvention | Polypeptide capable of binding PD1 and application thereof |
| abstract | The invention relates to a polypeptide capable of binding PD1, which is characterized by comprising 3 complementarity determining regions CDR1-3, the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NO. 1-17, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NO. 18-34, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO. 35-58. The invention aims at the polypeptide of PD1 to carry out nano antibody drug development and diagnostic kit development, and a nano antibody VHH specifically combined with PD1 is screened by preparing PD1 protein, immune alpaca, platform technology for displaying nano monoclonal antibody by using phage library and the like, and a CDR sequence of the nano antibody VHH is identified. The invention provides a potential nano-antibody new drug for clinical treatment of tumors and infectious diseases. |
| priorityDate | 2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 324.